Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

40results about How to "Therapeutically effective" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Modified nucleoside, nucleotide, and nucleic acid compositions

InactiveUS20130156849A1Therapeutically effectiveRaise hemoglobinOrganic active ingredientsPowder deliveryProtein precursorNucleotide

The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and / or activity.

Modified nucleoside, nucleotide, and nucleic acid compositions

View all

Owner:MODERNA THERAPEUTICS INC

Block Copolymer Compositions and Uses Thereof

InactiveUS20080247987A1Therapeutically effectiveMuscular disorderOintment deliveryPolymer chemistryCopolymer composition

The present invention describes compositions, devices, and methods for the production, use and administration of the composition having a non-thermoreversible block copolymer composition.

Block Copolymer Compositions and Uses Thereof

View all

Owner:ANGIOTECH INT AG (CH)

Biodegradable coating compositions including multiple layers

InactiveUS20060147491A1Avoiding toxic levelRate of releaseSurgeryCoatingsBiodegradable coatingBiomedical engineering

The invention provides devices for treatment of a patient, wherein at least a portion of the device is provided with a biodegradable coating composed of multiple coated layers of biodegradable material. The invention further provides methods of treatment utilizing the devices.

Biodegradable coating compositions including multiple layers

View all

Owner:SURMODICS INC

Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same

InactiveUS20040235712A1Therapeutically effectivePeptide/protein ingredientsGroup 8/9/10/18 element organic compoundsChemistryCoordination complex

In part, the present invention is directed to coordination complexes comprising a therapeutic agent. In one aspect, the subject compositions comprise a platinum metal center and a covalently attached therapeutic agent.

Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same

View all

Owner:MASSACHUSETTS INST OF TECH

Vectors and sequences for the treatment of diseases

ActiveUS8999948B2Increase chanceImproved profileNervous disorderHydrolasesDiseaseMedicine

The present invention provides new sequences, gene constructions, vectors and pharmaceutical compositions for the treatment of diseases and specially, for the treatment of mucopolysaccharidoses.

Vectors and sequences for the treatment of diseases

View all

Owner:ESTEVE PHARMA SA +1

Method of treatment of neurological injury or cancer by administration of dichloroacetate

InactiveUS20080221211A1Therapeutically effectiveBiocideElectrotherapyCancerMedicine

A method for treating neurological injury or cancer in a patient includes administration of a therapeutically-effective amount of dichloroacetic acid (DCA), a therapeutically-effective amount of electromagnetic radiation, or both to the patient.

Method of treatment of neurological injury or cancer by administration of dichloroacetate

View all

Owner:STREETER JACKSON

Use of certain drugs for treating nerve root injury

InactiveUS20080213283A1Therapeutically effectiveBiocideNervous disorderMammalDepressant

The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorder.

Owner:SCIATICON

Recombinant Sendai virus

InactiveUS7101685B2Improve expression levelReduce distanceSsRNA viruses negative-senseSugar derivativesViral replicationGenetics manipulation

A method for generating Sendai virus particles by transfecting the Sendai virus genome to a host expressing all genes for the initial viral replication has been developed, enabling the genetic manipulation of Sendai virus and effective utilization of said virus as the vector.

View all

Owner:DNAVEC RES

Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

InactiveUS7235259B2Improve aqueous concentrationEnhance solubilityPowder deliveryBiocideCholesteryl esterChemistry

A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

View all

Owner:PFIZER INC +1

Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same

InactiveUS7138520B2Therapeutically effectivePeptide/protein ingredientsGroup 8/9/10/18 element organic compoundsCoordination complexChemistry

View all

Owner:MASSACHUSETTS INST OF TECH

Anti-angiogenic cellular agent for cancer therapy

InactiveUS20080260701A1Effective treatmentTherapeutically effectiveBiocideGenetic material ingredientsAbnormal tissue growthHematopoietic cell

The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors.

Anti-angiogenic cellular agent for cancer therapy

View all

Owner:HOPE ERNEST G

A 19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for Anti-seizure therapy

ActiveUS20180177756A1Mitigation of impairmentTherapeutically effectiveNervous disorderOrganic chemistryMedicineAnticholinesterase Agents

This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with an therapeutically effective amount of an AED.

A 19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for Anti-seizure therapy

View all

Owner:ANAVEX LIFE SCI CORP

Functional Food Composition For Treating Allergy, Natural Tea Using the Same and the Manufacturing Method Thereof

InactiveUS20080311229A1Easy and regular administrationRapid therapeutic effectBiocidePre-extraction tea treatmentFunctional foodDisease

A functional food composition for treating allergy, comprising Saururus chinensis, Plantago asiatica, Poncirus trifoliata and Schisandra chinensis extracts, as active ingredients, a tea composition comprising the same and a manufacturing method thereof. The functional food and tea compositions for treatment of allergy in accordance with the present invention are therapeutically effective for any type of allergic diseases, irrespective of allergic causes. In particular, the tea composition advantageously enables easy and regular administration at need, which can achieve anti-allergic effects without particular efforts for treatment of diseases.

Functional Food Composition For Treating Allergy, Natural Tea Using the Same and the Manufacturing Method Thereof

View all

Owner:NAM JONG HYUN

Liposomal Formulations

InactiveUS20070224255A1Reduce adverse side effectsHigh encapsulation efficiencyAntiviralsPhosphorus organic compoundsDiseaseLiposome

The invention relates to formulations of hydrophilic substances encapsulated in liposomes, to the method of encapsulation of the hydrophilic substances in the liposomes and the use of said formulations in the prevention and / or treatment of diseases and / or disorders in humans and animals.

View all

Owner:ITALFARMACO SPA

Liposomal formulations

InactiveUS20090324709A1High encapsulation efficiencyNon-toxicBiocideAntiviralsDiseaseLiposome

View all

Owner:ITALFARMACO SPA

Vectors and sequences for the treatment of diseases

ActiveUS20150104863A1Increase chanceImproved profileNervous disorderVectorsGeneDisease cause

The present invention provides new sequences, gene constructions, vectors and pharmaceutical compositions for the treatment of diseases and specially, for the treatment of mucopolysaccharidoses.

View all

Owner:UNIV AUTONOMA DE BARCELONA +1

Novel GPCR and methods of use of the same

InactiveUS20090010909A1FunctionalFunction increaseOrganic active ingredientsNervous disorderCongestive heart failure chfIschemic Heart Diseases

The present invention relates to methods of identifying antagonists of GPR22, a G protein-coupled receptor (GPCR) and related compositions and methods. Antagonists of GPR22 are useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.

Novel GPCR and methods of use of the same

View all

Owner:BURNHAM INST FOR MEDICAL RES

Plant extracts with Anti-diabetic and other useful activities

PendingUS20160022752A1Therapeutically effectiveRemarkable effectCompound screeningBiocideDiseaseInsulin-like growth factor

This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible cure of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling. This regulatory effect may include modulations of the levels and / or activity of the Insulin Receptor (IR), the Insulin-like Growth Factor (IGF) Receptor, and / or the Insulin Receptor Substrate (IRS) proteins in cells and tissues in the body.

Plant extracts with Anti-diabetic and other useful activities

View all

Owner:HOUSEY PHARMA RES LAB L L C

Nucleic acid inhibitors of glutamate receptors

ActiveUS20060148746A1Therapeutically effectiveInhibitionNervous disorderSugar derivativesDiseaseMetabotropic glutamate receptor 4

The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i.e., SELEX and laser pulse photolysis for the selection and screening of aptamers that inhibit receptor function and are useful therefore, in the treatment of diseases associated with excessive activation of ionotropic glutamate receptors.

Nucleic acid inhibitors of glutamate receptors

View all

Owner:THE RES FOUND OF STATE UNIV OF NEW YORK +1

Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2

InactiveUS20050020657A1Reduce severityShorten the durationBiocideNervous disorderThromboxane A2 receptorCyclooxygenase

The invention is directed to methods and compositions that can be used in the treatment of inflammation, pain and cardiovascular disorders. Methods and compositions are described involving the combination of a thromboxane A2 receptor antagonist and an inhibitor specific for cyclooxygenase-2.

Owner:B M R A CORP

Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor

InactiveUS20060211654A1Increase concentrationImprove solubilityAntibacterial agentsPowder deliveryCholesterylester transfer proteinCholesteryl ester

A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor

View all

Owner:BEND RES

Methods, compositions, and kits for predicting the effect of compounds on hot flash symptoms

InactiveUS20050064462A1Prevent and treat osteoporosisAvoid symptomsBiocideMicrobiological testing/measurementHot flashMedicine

The present invention provides methods, compositions, and kits, for determining the effects of one or more candidate compounds on hot flash symptoms. In certain aspects, the methods, compositions, and kits can be used to identify compounds that decrease the incidence of hot flash symptoms. In other aspects, the methods, compositions, and kits can be used to determine whether candidate compounds increase the incidence of undesirable hot flash symptoms when administered to a subject.

Methods, compositions, and kits for predicting the effect of compounds on hot flash symptoms

View all

Owner:SIGNAL PHARM INC

Skin care composition

InactiveUS20180325973A1Therapeutically effectiveCosmetic preparationsToilet preparationsAtopic dermatitisAD - Atopic dermatitis

The present invention relates to skin care compositions comprising extract or juice from the plant Kalanchoe daigremontiana for topical administration to human skin and methods of making said compositions. The compositions are therapeutically effective for hydrating and conditioning the skin and are shown to be clinically effective at treating dermal conditions or skin disorders, in particular, psoriasis, atopic dermatitis or allergic contact dermatitis.

View all

Owner:ISN PHARMA SP ZOO

Phenoxypropanol connected with phenylpiperazine and phenoxyalkylamine terminal in its side chain

InactiveUS6846826B2Maintain hypotensionInducing effectBiocideOrganic chemistryPhenylpiperazineHalogen

Certain 1,4-dihydropyridine compounds, useful as adrenergic blocking agents and as calcium channel blocking agents, the compounds having the formula wherein R1 is hydrogen, halogen, C1-6-alkyl, or C1-6-alkoxy, R3 is hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy, or CF3(CH2)nO— wherein n is 1, 2, or 3, and R5 is —NHCH2CH2O— or —N(CH2CH2)2N—.

Phenoxypropanol connected with phenylpiperazine and phenoxyalkylamine terminal in its side chain

View all

Owner:LIN TONG HO +1

Skin care composition

InactiveUS20200030398A1Therapeutically effectiveCosmetic preparationsAerosol deliveryPharmacologyPsoriasis universalis

The present invention relates to methods of skin care or treating dermal conditions characterized by itching, skin redness, skin roughness, keratosis and squama, the method comprising: applying a composition for topical administration comprising a therapeutically effective amount of Kalanchoe daigremontiana extract or juice to an affected area. The compositions are therapeutically effective for hydrating and conditioning the skin and are shown to be clinically effective at treating dermal conditions or skin disorders, in particular, psoriasis, atopic dermatitis or allergic contact dermatitis.

View all

Owner:ISN PHARMA SP ZOO

N-lipoic-amino acid or peptide, derivatives and their uses

ActiveUS20190161467A1Therapeutically effectiveReduce impactCosmetic preparationsPeptide/protein ingredientsAmino acidPeptide

Novel compounds of N-Lipoic-amino acid, N-Lipoic-peptides and their derivatives are described. Also described are compositions and method of compositions containing the derivatives of the amino acids or peptides, and their uses including treating and preventing dermatological or cosmetic conditions or other disorders of the cutaneous system. Compositions and methods of using the compositions for skin lightening and cosmetics are also disclosed.

N-lipoic-amino acid or peptide, derivatives and their uses

View all

Owner:NEOSTRATA

Novel NANO gold and process for preparation

InactiveUS20140234439A1Non toxicSmall particle sizeHeavy metal active ingredientsMaterial nanotechnologyFerulaGranularity

This invention relates to bio synthesis of novel nano gold through environment friendly process with the aid of plant materials classified under the taxonomical genus Dalbergia, Citrus, Ferula and Dolichos or Macrotyloma. The present inventive product novel nano gold finds utility in, the treatment of humans and animals, nutraceutical, cosmeceutical and herbal composition, the field of technology including but not limited to nano technology, green technology and bio technology. The invention also relates to the use of plant materials in the purification and particle size reduction of metals.

Owner:BENDALE YOH N +1